RUBRACA (rucaparib)

TherapyPharma&

RUBRACA (rucaparib) from Pharma& is a PARP inhibitor used in biomarker-defined ovarian and prostate cancers.

Approvals

Indications

Biomarkers

Mapped tests

Where this therapy is approved with a companion diagnostic

Each row represents a defined combination of indication, biomarker criteria, and RUBRACA. Select a testing pathway to see the eligible companion diagnostic tests.

Indication-specific approvals

Approvals where RUBRACA is tied to a specific indication and biomarker definition.

Indication	Biomarker criteria	Notes
Ovarian Cancer Solid Tumor · Ovary	BRCA1 alterations (including mutations)		View testing pathway →
Metastatic Castrate Resistant Prostate Cancer (mCRPC) Solid Tumor · Prostate	BRCA1 alterations (including mutations)		View testing pathway →

Tumor-agnostic approvals

Approvals defined at the solid tumor level where biomarker criteria determine eligibility for RUBRACA.

No tumor-agnostic companion diagnostic approvals are currently mapped for this therapy.

Tests used in these approvals

These assays are identified in FDA labeling or sponsor materials as companion diagnostics or acceptable tests when considering RUBRACA for eligible patients.

Test

BRACAnalysis CDx

Myriad Genetics

Method

PCR

Specimen

Whole blood

1 approvalView test profile →

Test

FoundationOne Liquid CDx

Foundation Medicine, Inc.

Method

NGS

Specimen

Whole blood

1 approvalView test profile →

This view is scoped to RUBRACA (rucaparib). You can also see how it compares with other therapies and indications on the main Know Your Companions™ map.